CN103796674A - 具有用于使至少一种抗原靶向树突状细胞的工具的组合物 - Google Patents

具有用于使至少一种抗原靶向树突状细胞的工具的组合物 Download PDF

Info

Publication number
CN103796674A
CN103796674A CN201280036278.3A CN201280036278A CN103796674A CN 103796674 A CN103796674 A CN 103796674A CN 201280036278 A CN201280036278 A CN 201280036278A CN 103796674 A CN103796674 A CN 103796674A
Authority
CN
China
Prior art keywords
antigen
toxin
dendritic cells
targeting
shiga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280036278.3A
Other languages
English (en)
Chinese (zh)
Inventor
E·塔投尔
L·乔哈尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Universite Paris Descartes
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Curie, Universite Paris Descartes filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of CN103796674A publication Critical patent/CN103796674A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201280036278.3A 2011-07-22 2012-07-23 具有用于使至少一种抗原靶向树突状细胞的工具的组合物 Pending CN103796674A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305959.6 2011-07-22
EP11305959A EP2548571A1 (en) 2011-07-22 2011-07-22 Compositions having means for targeting at least one antigen to dendritic cells
PCT/EP2012/064425 WO2013014128A1 (en) 2011-07-22 2012-07-23 Compositions having means for targeting at least one antigen to dendritic cells

Publications (1)

Publication Number Publication Date
CN103796674A true CN103796674A (zh) 2014-05-14

Family

ID=46548478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036278.3A Pending CN103796674A (zh) 2011-07-22 2012-07-23 具有用于使至少一种抗原靶向树突状细胞的工具的组合物

Country Status (9)

Country Link
US (2) US20140199379A1 (enExample)
EP (2) EP2548571A1 (enExample)
JP (1) JP2014523918A (enExample)
CN (1) CN103796674A (enExample)
AU (1) AU2012288949B2 (enExample)
CA (1) CA2841036A1 (enExample)
IL (1) IL230525A0 (enExample)
IN (1) IN2014DN00078A (enExample)
WO (1) WO2013014128A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104277094A (zh) * 2014-07-04 2015-01-14 文康医疗技术（深圳）有限公司 Dc靶向肽及其应用
CN110869048A (zh) * 2017-05-03 2020-03-06 新加坡科技研究局 刺激树突细胞(DC)前体细胞群“pre-DC”的方法及其用途
CN115724992A (zh) * 2022-07-25 2023-03-03 江南大学 一种志贺毒素b亚基与抗原偶联物及其制备方法与应用
WO2023070317A1 (zh) * 2021-10-26 2023-05-04 江苏省农业科学院 基于dc细胞的双功能纳米抗体及其构建方法和应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2953287A1 (en) * 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CA2986687A1 (en) * 2015-05-22 2016-12-01 Brian J. Czerniecki Manufacturing multi-dose injection ready dendritic cell vaccines
WO2016199904A1 (ja) * 2015-06-10 2016-12-15 国立大学法人東京大学 ワクチン用アジュバント、ワクチン、及び免疫誘導方法
US20190010236A1 (en) * 2015-12-29 2019-01-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2020245321A1 (en) * 2019-06-04 2020-12-10 Institut Curie METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
GB202411940D0 (en) * 2024-08-13 2024-09-25 Univ Exeter Anti-CLEC12A Antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766193B1 (fr) 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
EP1229045A1 (en) 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
GB0524409D0 (en) 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLIVE KS ET AL: "Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?", 《EXPERT REVIEW OF VACCINES》 *
HAICHEUR N ET AL: "The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens", 《JOURNAL OF IMMUNOLOGY》 *
HAINING WN ET AL: "CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans", 《CLINICAL CANCER RESEARCH》 *
VINGERT B ET AL: "The Shiga toxin B-subunit targets antigenin vivo to dendritic cells and elicits anti-tumor immunity", 《EUROPEAN JOURNAL OF IMMUNOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104277094A (zh) * 2014-07-04 2015-01-14 文康医疗技术（深圳）有限公司 Dc靶向肽及其应用
CN110869048A (zh) * 2017-05-03 2020-03-06 新加坡科技研究局 刺激树突细胞(DC)前体细胞群“pre-DC”的方法及其用途
WO2023070317A1 (zh) * 2021-10-26 2023-05-04 江苏省农业科学院 基于dc细胞的双功能纳米抗体及其构建方法和应用
CN115724992A (zh) * 2022-07-25 2023-03-03 江南大学 一种志贺毒素b亚基与抗原偶联物及其制备方法与应用

Also Published As

Publication number Publication date
IN2014DN00078A (enExample) 2015-05-15
CA2841036A1 (en) 2013-01-31
AU2012288949A1 (en) 2013-04-11
AU2012288949B2 (en) 2014-05-01
EP2734225A1 (en) 2014-05-28
US20140199379A1 (en) 2014-07-17
US20170042994A1 (en) 2017-02-16
JP2014523918A (ja) 2014-09-18
EP2548571A1 (en) 2013-01-23
WO2013014128A1 (en) 2013-01-31
IL230525A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
AU2012288949B2 (en) Compositions having means for targeting at least one antigen to dendritic cells
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
JP6306700B2 (ja) アルブミン改変体及びその使用
TW200533681A (en) Immunogenic peptide carrier conjugates and methods of producing same
CN102448485B (zh) 免疫原性组合物及其用途
Renaudet et al. Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity
FR2955773A1 (fr) Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
Ito et al. Antigen/adjuvant-displaying enveloped viral replica as a self-adjuvanting anti-breast-cancer vaccine candidate
US20070053920A1 (en) Nematode polypeptide adjuvant
Xu et al. Development of an enzyme-mediated, site-specific method to conjugate toll-like receptor 2 agonists onto protein antigens: toward a broadly protective, four component, group A streptococcal self-adjuvanting lipoprotein–fusion combination vaccine
US20090214598A1 (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
US20230390369A1 (en) Chimeric antigen comprising the extracellular domain of pd-l1
Guy Adjuvants for protein-and carbohydrate-based vaccines
CN121086057A (zh) 膜联蛋白的核心结构域及其在抗原递送和接种中的用途
WO2025075173A1 (ja) 免疫原性キャリア及び免疫原性組成物
WO2023161528A1 (en) A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
Buskas et al. Semisynthetic and Fully Synthetic Carbohydrate‐Based Cancer Vaccines
Zeng et al. Soluble Proteins Induce Strong CD8+ T Cell
HK1130687A (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140514